Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Illustrates the Difficulty Diagnosing Granulomatosis with Polyangiitis

Diana Girnita, MD, PhD, & Vishnuteja Devalla, MD  |  Issue: June 2018  |  June 21, 2018

Over the course of the next year, the patient has experienced complete resolution of virtually all of his symptoms, has been successfully tapered off of prednisone without any recurrence of symptoms and is tolerating methotrexate without any major adverse reactions. He continues to follow up with rheumatology regularly.

Discussion

Figure 2. A nasal biopsy shows giant multinuclear cells (black arrow).

Figure 2. A nasal biopsy shows giant multinuclear cells (black arrow).

GPA is a complex, multisystem disease that is often difficult to diagnose, especially at the initial presentation. Early diagnosis is critical to halt the disease process and progression. Patients with GPA diagnosed early in the disease process, especially in the ambulatory setting, have had favorable outcomes compared with patients enrolled in randomized controlled trials who are usually referred to tertiary centers and present with advanced disease.4 This can certainly be attributed to the delay in diagnosis and or misinterpretation of initial presenting symptoms.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Without increased awareness and proper training to recognize this disease, physicians often omit a vasculitis diagnosis from their differentials. Reported symptoms include, but are not limited to, fatigue, fever, weight loss, arthralgias, rhinosinusitis, cough, voice changes, hearing loss, dyspnea and skin rashes.

Although our patient had a strikingly similar presentation, he was officially diagnosed with GPA eight years after the onset of symptoms. During the five years between the worsening of his symptoms and the diagnosis of GPA, we have been able to track multiple medical visits. Our patient had visited his primary care physician, ENT and infectious disease specialists, as well as made multiple emergency department visits due to recurrent, debilitating symptoms.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A delay in diagnosis can often be fatal. Therefore, establishing a diagnosis early in the disease process is crucial. In 1990, the ACR established criteria to help distinguish GPA from other forms of vasculitis.5 The following criteria were proposed and studied: nasal or oral inflammation (painful or painless oral ulcers, or purulent or bloody nasal discharge), abnormal chest radiograph showing nodules, fixed infiltrates or cavities, abnormal urinary sediment (microscopic hematuria with or without red cell casts) and granulomatous inflammation on biopsy of an artery or perivascular area. The presence of two or more of these four criteria yielded a sensitivity and specificity of 88% and 92% respectively.5 Based on ACR criteria, our patient was diagnosed with GPA.

Once the diagnosis has been suspected clinically, several laboratory markers have been recognized to differentiate GPA from other forms of vasculitis. In 1985, ANCA were linked to GPA.6 Immunofluorescence patterns described in ANCA vasculitis were either diffuse within the cytoplasm (C-ANCA) or perinuclear (P-ANCA).7 Two relevant target antigens, proteinase 3 (PR3) and myeloperoxidase (MPO) located in the azurophilic granules of neutrophils and the peroxidase-positive lysosomes of monocytes were found in ANCA vasculitis. Antibodies that target PR3 and MPO antigens are called PR3-ANCA and MPO-ANCA, respectively.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Vasculitis Tagged with:ANCAanti-neutrophil cytoplasmic antibodies (ANCA)BiomarkersbiopsyGPAgranulomatosis with polyangiitis

Related Articles
    Figure 2: Renal Biopsy

    The Classification & Diagnosis of Granulomatosis with Polyangiitis

    August 16, 2018

    Based on the classification system developed by the Chapel Hill Consensus Conference, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is defined as a necrotizing vasculitis involving small vessels that is associated with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA and displays minimal immune deposits. The mechanism behind the pathogenesis of ANCA-associated vasculitis is not fully…

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    ACR Winter Rheumatology Symposium: Tips for ANCA Testing

    May 1, 2013

    How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences